ZA200303729B - Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. - Google Patents
Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. Download PDFInfo
- Publication number
- ZA200303729B ZA200303729B ZA200303729A ZA200303729A ZA200303729B ZA 200303729 B ZA200303729 B ZA 200303729B ZA 200303729 A ZA200303729 A ZA 200303729A ZA 200303729 A ZA200303729 A ZA 200303729A ZA 200303729 B ZA200303729 B ZA 200303729B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- receptor
- agonists
- pharmaceutical composition
- antagonists
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 70
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title description 40
- 239000002126 C01EB10 - Adenosine Substances 0.000 title description 21
- 229960005305 adenosine Drugs 0.000 title description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 20
- 239000005557 antagonist Substances 0.000 claims description 19
- 108050000203 Adenosine receptors Proteins 0.000 claims description 18
- 102000009346 Adenosine receptors Human genes 0.000 claims description 18
- 208000006673 asthma Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 210000003630 histaminocyte Anatomy 0.000 claims description 5
- 201000006370 kidney failure Diseases 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 230000002207 retinal effect Effects 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010039897 Sedation Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000036280 sedation Effects 0.000 claims description 4
- 206010047139 Vasoconstriction Diseases 0.000 claims description 3
- 102000030621 adenylate cyclase Human genes 0.000 claims description 3
- 108060000200 adenylate cyclase Proteins 0.000 claims description 3
- 208000006218 bradycardia Diseases 0.000 claims description 3
- 230000036471 bradycardia Effects 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 210000003733 optic disk Anatomy 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 230000035176 regulation of the force of heart contraction Effects 0.000 claims description 3
- 230000025033 vasoconstriction Effects 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- 108090000371 Esterases Proteins 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 15
- 101150046889 ADORA3 gene Proteins 0.000 claims 11
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims 8
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 4
- 206010006482 Bronchospasm Diseases 0.000 claims 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 4
- 229940127473 Prostaglandin Receptor Agonists Drugs 0.000 claims 4
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 4
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 claims 4
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 claims 4
- 230000007885 bronchoconstriction Effects 0.000 claims 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 4
- 239000000064 cholinergic agonist Substances 0.000 claims 4
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 101150007969 ADORA1 gene Proteins 0.000 claims 3
- 101150051188 Adora2a gene Proteins 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000012044 organic layer Substances 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 claims 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims 2
- 239000000775 AMPA receptor antagonist Substances 0.000 claims 2
- 229940098747 AMPA receptor antagonist Drugs 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 101150049660 DRD2 gene Proteins 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 229940123100 Dopamine D1 receptor antagonist Drugs 0.000 claims 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims 2
- 102000002045 Endothelin Human genes 0.000 claims 2
- 108050009340 Endothelin Proteins 0.000 claims 2
- 102000010180 Endothelin receptor Human genes 0.000 claims 2
- 108050001739 Endothelin receptor Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 229930010555 Inosine Natural products 0.000 claims 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 2
- 108090000862 Ion Channels Proteins 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 102000005157 Somatostatin Human genes 0.000 claims 2
- 108010056088 Somatostatin Proteins 0.000 claims 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 229940127282 angiotensin receptor antagonist Drugs 0.000 claims 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000003537 cannabinoid receptor agonist Substances 0.000 claims 2
- 229940121376 cannabinoid receptor agonist Drugs 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 239000000433 dopamine 1 receptor blocking agent Substances 0.000 claims 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 2
- 229960003199 etacrynic acid Drugs 0.000 claims 2
- 239000003635 glucocorticoid antagonist Substances 0.000 claims 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229960003786 inosine Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000006742 locomotor activity Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 230000003551 muscarinic effect Effects 0.000 claims 2
- 239000004090 neuroprotective agent Substances 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 239000002840 nitric oxide donor Substances 0.000 claims 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 claims 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 239000002461 renin inhibitor Substances 0.000 claims 2
- 229940086526 renin-inhibitors Drugs 0.000 claims 2
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 claims 2
- 239000000952 serotonin receptor agonist Substances 0.000 claims 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 229960000553 somatostatin Drugs 0.000 claims 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims 2
- 108090000721 thyroid hormone receptors Proteins 0.000 claims 2
- 102000004217 thyroid hormone receptors Human genes 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010030302 Oliguria Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 239000012298 atmosphere Substances 0.000 claims 1
- 239000012267 brine Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000013010 irrigating solution Substances 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000011224 negative regulation of urine volume Effects 0.000 claims 1
- 230000011242 neutrophil chemotaxis Effects 0.000 claims 1
- 239000012299 nitrogen atmosphere Substances 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
- 239000002536 vasopressin receptor antagonist Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 5
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001300 stimulation of adenylate cyclase Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940103988 Adenosine uptake inhibitor Drugs 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
| US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200303729B true ZA200303729B (en) | 2004-05-14 |
Family
ID=27419112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200303729A ZA200303729B (en) | 2000-12-01 | 2003-05-14 | Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1347980A4 (hu) |
| JP (1) | JP4579497B2 (hu) |
| CN (1) | CN1263757C (hu) |
| AP (1) | AP1893A (hu) |
| AU (1) | AU2002248151B2 (hu) |
| BR (1) | BR0115847A (hu) |
| CA (1) | CA2430577A1 (hu) |
| CZ (1) | CZ20031831A3 (hu) |
| EA (1) | EA007254B1 (hu) |
| HU (1) | HUP0400692A3 (hu) |
| IL (1) | IL155962A0 (hu) |
| ME (1) | MEP35308A (hu) |
| MX (1) | MXPA03004717A (hu) |
| NO (1) | NO327207B1 (hu) |
| NZ (1) | NZ525885A (hu) |
| OA (1) | OA13295A (hu) |
| PL (1) | PL363245A1 (hu) |
| WO (1) | WO2002057267A1 (hu) |
| YU (1) | YU42703A (hu) |
| ZA (1) | ZA200303729B (hu) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
| WO1999062518A1 (en) | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| DE10148883A1 (de) | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
| EP2050751A1 (en) | 2001-11-30 | 2009-04-22 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| US20030199526A1 (en) * | 2001-12-07 | 2003-10-23 | Deborah Choquette | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| CN1816551A (zh) | 2001-12-20 | 2006-08-09 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도 |
| CA2502429A1 (en) * | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| EP3719018A1 (en) | 2006-04-25 | 2020-10-07 | Astex Therapeutics Ltd | Purine and deazapurine derivatives as pharmaceutical compounds |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
| KR101494734B1 (ko) | 2007-10-11 | 2015-02-26 | 아스트라제네카 아베 | 단백질 키나제 ｂ 억제제로서 피롤로[2,3-ｄ]피리미딘 유도체 |
| AP2010005347A0 (en) | 2008-01-11 | 2010-08-31 | Natco Pharma Ltd | Novel pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| MY169449A (en) | 2011-04-01 | 2019-04-11 | Astrazeneca Ab | Therapeutic treatment |
| DK2785349T4 (da) | 2011-11-30 | 2023-01-09 | Astrazeneca Ab | Kombinationsbehandling af cancer |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2013182580A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| US9662311B2 (en) * | 2013-06-21 | 2017-05-30 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
| SG10201710705UA (en) | 2013-06-21 | 2018-02-27 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| HUE064003T2 (hu) * | 2015-01-20 | 2024-02-28 | Wuxi Fortune Pharmaceutical Co Ltd | JAK-gátló |
| ES2734048T3 (es) | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidores de Janus cinasas (JAK) |
| MX2017013797A (es) | 2015-05-29 | 2018-03-21 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidor de janus quinasa. |
| CN105771672B (zh) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法 |
| CN108570054B (zh) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
| BR112020024700A2 (pt) * | 2018-06-04 | 2021-03-02 | Exscientia Ltd | compostos de pirazolopirimidina como antagonistas receptores de adenosina |
| CN110128316B (zh) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
| CN110272373B (zh) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | 一种具有选择性的腺苷a1受体拮抗剂及其应用 |
| CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990067704A (ko) * | 1992-12-17 | 1999-08-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물 |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| WO1999062518A1 (en) * | 1998-06-02 | 1999-12-09 | Osi Pharmaceuticals, Inc. | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE |
| IL149935A0 (en) * | 1999-12-02 | 2002-11-10 | Osi Pharm Inc | Compounds specific to adenosine a1, a2a and a3 receptors and uses thereof |
| EP2050751A1 (en) * | 2001-11-30 | 2009-04-22 | OSI Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
-
2001
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ525885A (en) | 2005-01-28 |
| JP2004517896A (ja) | 2004-06-17 |
| IL155962A0 (en) | 2003-12-23 |
| CZ20031831A3 (cs) | 2004-05-12 |
| HUP0400692A2 (hu) | 2004-07-28 |
| CN1263757C (zh) | 2006-07-12 |
| EA200300628A1 (ru) | 2003-12-25 |
| NO20032482D0 (no) | 2003-06-02 |
| MXPA03004717A (es) | 2004-06-30 |
| CN1489590A (zh) | 2004-04-14 |
| CA2430577A1 (en) | 2002-07-25 |
| EA007254B1 (ru) | 2006-08-25 |
| JP4579497B2 (ja) | 2010-11-10 |
| YU42703A (sh) | 2006-03-03 |
| OA13295A (en) | 2007-04-13 |
| MEP35308A (en) | 2011-02-10 |
| EP1347980A4 (en) | 2005-02-09 |
| AP2003002807A0 (en) | 2003-06-30 |
| AU2002248151B2 (en) | 2008-02-21 |
| NO20032482L (no) | 2003-07-28 |
| AP1893A (en) | 2008-09-23 |
| PL363245A1 (en) | 2004-11-15 |
| BR0115847A (pt) | 2004-02-25 |
| HUP0400692A3 (en) | 2007-09-28 |
| EP1347980A1 (en) | 2003-10-01 |
| NO327207B1 (no) | 2009-05-11 |
| WO2002057267A1 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200303729B (en) | Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof. | |
| KR100840727B1 (ko) | 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법 | |
| US6770666B2 (en) | Fused-ring compounds and use thereof as drugs | |
| JP4611524B2 (ja) | ピロロ［２，３ｄ］ピリミジン組成物およびその使用 | |
| US6664252B2 (en) | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof | |
| DE60018216T2 (de) | Kondensierte purinderivate | |
| US20040082635A1 (en) | Fused cyclic compounds and medicinal use thereof | |
| AU757290B2 (en) | Imidazolone anorectic agents: II. phenyl derivatives | |
| CA2468673C (en) | Compounds specific to adenosine a1 and a3 receptors and uses thereof | |
| AU2002248151A1 (en) | Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof | |
| EP1798233A1 (en) | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof | |
| EP1162196A1 (en) | Fused-ring compounds and use thereof as drugs | |
| KR20070072598A (ko) | 인돌 및 벤지미다졸 유도체 | |
| JP2003505376A (ja) | ベンズイミダゾロン誘導体およびそのホスホジエステラーゼ阻害剤としての用途 | |
| EP1513589B1 (en) | 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma | |
| KR100395356B1 (ko) | 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노인돌 화합물 | |
| JP2002523507A (ja) | ジヒドロ−［１，２，３］トリアゾロ−［４，５−ｄ］ピリミジン−７−オン | |
| CN102985425A (zh) | 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 | |
| JPH07258221A (ja) | ベンゾイミダゾール、これらの化合物を含む医薬組成物及びそれらの調製方法 | |
| NZ263614A (en) | Pharmaceutical use of 5-(methylaminosulphonylmethyl)-3- (n-methylpyrrolidin-2-ylmethyl)-1h-indole and of the corresponding -3-(pyrrolidin-2-ylmethyl)-derivative | |
| KR20010032435A (ko) | 5-(2-이미다졸리닐아미노)벤즈이미다졸 유도체, 그의 제조및 대사 안정성이 개선된 알파-아드레날린수용체아고니스트로서의 그의 용도 | |
| WO2016146602A1 (de) | Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung | |
| JP2003212846A (ja) | 縮合環化合物及びｃ型肝炎治療剤 | |
| CZ394492A3 (en) | Benzimidazole derivatives, process of their preparation and pharmaceutical preparations in which said derivatives are comprised | |
| JP7143437B2 (ja) | Ｆｍｓ様チロシンキナーゼ阻害剤 |